The Joint Corp (JYNT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
The Joint Corp stock (JYNT) is currently trading at $8.41. The Joint Corp PS ratio (Price-to-Sales) is 2.22. Analyst consensus price target for JYNT is $10.00. WallStSmart rates JYNT as Sell.
- JYNT PE ratio analysis and historical PE chart
- JYNT PS ratio (Price-to-Sales) history and trend
- JYNT intrinsic value — DCF, Graham Number, EPV models
- JYNT stock price prediction 2025 2026 2027 2028 2029 2030
- JYNT fair value vs current price
- JYNT insider transactions and insider buying
- Is JYNT undervalued or overvalued?
- The Joint Corp financial analysis — revenue, earnings, cash flow
- JYNT Piotroski F-Score and Altman Z-Score
- JYNT analyst price target and Smart Rating
The Joint Corp
📊 No data available
Try selecting a different time range
Smart Analysis
The Joint Corp (JYNT) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in eps growth, institutional own.. Concerns around market cap and peg ratio. Mixed signals suggest waiting for clearer direction before acting.
The Joint Corp (JYNT) Key Strengths (2)
Earnings per share surging 6277.00% year-over-year
78.53% of shares held by major funds and institutions
Supporting Valuation Data
The Joint Corp (JYNT) Areas to Watch (8)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Near-zero operating margins, business under pressure
Very expensive at 7.7x book value
Revenue growing slowly at 3.10% annually
Micro-cap company with very limited liquidity and high volatility
Thin profit margins with limited profitability
Revenue is fairly priced at 2.22x sales
The Joint Corp (JYNT) Detailed Analysis Report
Overall Assessment
This company scores 37/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 2 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own.. Growth metrics are encouraging with EPS Growth at 6277.00%.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (2.22), Price/Book (7.70) suggest expensive pricing. Growth concerns include Revenue Growth at 3.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -1.50%, Operating Margin at 4.25%, Profit Margin at 5.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 3.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
JYNT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
JYNT's Price-to-Sales ratio of 2.22x sits near its historical average of 2.34x (17th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 10% below its historical high of 2.47x set in Mar 2026, and 1% above its historical low of 2.21x in Mar 2026.
Compare JYNT with Competitors
Top MEDICAL CARE FACILITIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for The Joint Corp (JYNT) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
The Joint Corp operates as a stable business with moderate growth and solid fundamentals. Revenue reached 55M with 3% growth year-over-year. Profit margins are thin at 5.3%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Generating 3M in free cash flow and 3M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of 0.09 indicates a conservative balance sheet with 31M in cash.
What to Watch Next
Margin expansion: can The Joint Corp push profit margins above 15% as the business scales?
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact The Joint Corp.
Bottom Line
The Joint Corp offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(9 last 3 months)
| Insider | Type | Shares |
|---|---|---|
JOBSON, CHARLES E 10% Owner | Buy | +15,397 |
| Insider | Type | Shares |
|---|---|---|
JOBSON, CHARLES E 10% Owner | Buy | +448 |
| Insider | Type | Shares |
|---|---|---|
JOBSON, CHARLES E 10% Owner | Buy | +725 |
| Insider | Type | Shares |
|---|---|---|
JOBSON, CHARLES E 10% Owner | Buy | +16,753 |
| Insider | Type | Shares |
|---|---|---|
JOBSON, CHARLES E 10% Owner | Buy | +5,240 |
| Insider | Type | Shares |
|---|---|---|
JOBSON, CHARLES E 10% Owner | Buy | +1,393 |
| Insider | Type | Shares |
|---|---|---|
JOBSON, CHARLES E 10% Owner | Buy | +11 |
Data sourced from SEC Form 4 filings
Last updated: 2:28:48 PM
About The Joint Corp(JYNT)
NASDAQ
HEALTHCARE
MEDICAL CARE FACILITIES
USA
The Joint Corp. The company is headquartered in Scottsdale, Arizona.